Skip to Content


Active Substance: fomivirsen
Common Name: fomivirsen
ATC Code: S01AD08
Marketing Authorisation Holder: Novartis Ophthalmics Europe Ltd.
Active Substance: fomivirsen
Status: Withdrawn
Authorisation Date: 1999-07-29
Therapeutic Area: Cytomegalovirus Retinitis HIV Infections
Pharmacotherapeutic Group: Ophthalmologicals

Therapeutic Indication

For the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immuno-deficiency syndrome (AIDS).
Until further experience is gained, fomivirsen should be used only when other therapy has been ineffective or is considered unsuitable.

The marketing authorisation for Vitravene has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.